Testing a new treatment to reduce brain inflammation in Alzheimer's disease

Plain-English translation of NCT06745583 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is an early-stage research study testing a new medication called EI-1071 in people with Alzheimer's disease. The main goal is to understand whether the medication is safe to take and whether it can reduce harmful inflammation in the brain—a process that may contribute to Alzheimer's symptoms and progression. Researchers will use special brain imaging scans to see if the medication is working as intended.

Alzheimer's disease involves harmful inflammation in the brain that damages nerve cells and causes memory loss and thinking problems. This medication targets a specific type of brain cell involved in that inflammation, so researchers want to see if blocking it could slow or reduce symptoms.

Do you qualify?

You likely qualify if…

you have been diagnosed with mild, moderate, or severe Alzheimer's disease
you have objective evidence of cognitive impairment confirmed at screening
your blood work shows healthy kidney, liver, and blood cell counts
if you are taking Alzheimer's medications, your doses have been stable for at least 8 weeks
you are willing to use effective contraception during the study (if you can become pregnant or father a child)

You likely don't qualify if…

you weigh 150 kg (330 lbs) or more, or have a BMI of 35 or higher
you have taken pexidartinib (Turalio) or other similar drugs targeting CSF-1 in the past 3 months
you are pregnant, breastfeeding, or planning to become pregnant during the study
you have active or chronic infections including tuberculosis, hepatitis B or C, or HIV
you have a specific genetic marker (TSPO rs6971 polymorphism) that would prevent the study imaging from working properly

What participation looks like

You would receive the medication (EI-1071) as part of the study. You would have screening visits to check that you are healthy enough to participate, and then regular study visits where researchers will check how you are responding to the treatment. Special brain imaging scans (PET/MRI) will be done to see if the medication is reducing inflammation in your brain, and blood tests will track inflammatory markers related to Alzheimer's. The study will closely monitor your safety throughout.

AI-generated summary from trial data · Jun 13, 2026 · Not medical advice

Trial locations(2 sites)

Taiwan

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei